Kringle Pharma Inc

Chart & Performance

D1W1MN

P/E

—

P/S

24.78

EPS

—

Div Yield, %

—

Shrs. gr., 5y

10.11%

Rev. gr., 5y

-31.17%

Revenues

72m

-9.77%

Net income

-916m

L+21.13%

CFO

-756m

L+14.31%

Notes

No notes on this company yet

Write a private note on this company, for your eyes only

Profile

Kringle Pharma, Inc. specializes in the innovation, production, and distribution of hepatocyte growth factor (HGF) protein-based therapeutics aimed at regenerative medicine. The company's cutting-edge HGF solutions are designed to address serious medical conditions including acute spinal cord injury, amyotrophic lateral sclerosis, vocal fold scars, and acute kidney injury. Founded in 2001, Kringle Pharma operates from its base in Ibaraki, Japan.

URL

https://www.kringle-pharma.com/

IPO date

Dec 28, 2020

Employees

Domiciled in

Incorporated in

Valuation

Order:

Title JPY in thousands, except ratios and share amounts	FY	FY	FY	FY	FY	FY	FY	FY
Title JPY in thousands, except ratios and share amounts	2025‑09	2024‑09	2023‑09	2022‑09	2021‑09	2020‑09	2019‑09	2018‑09
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT